Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of HepG2.2.15 cell autophagy corpuscle in preparing hepatitis b virus (HBV) therapeutic vaccines

A therapeutic vaccine and autophagosome technology, applied in animal cells, tumor/cancer cells, antibody medical components, etc., can solve the problems of no therapeutic vaccine approved for marketing and unstable overall curative effect

Active Publication Date: 2013-10-09
SOUTHEAST UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although therapeutic vaccines can induce an immune response against HBV, the overall curative effect on HBV virus suppression and serological changes is not stable, so far no therapeutic vaccine has been approved for marketing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HepG2.2.15 cell autophagy corpuscle in preparing hepatitis b virus (HBV) therapeutic vaccines
  • Application of HepG2.2.15 cell autophagy corpuscle in preparing hepatitis b virus (HBV) therapeutic vaccines
  • Application of HepG2.2.15 cell autophagy corpuscle in preparing hepatitis b virus (HBV) therapeutic vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Preparation of autophagosome HBV-DRibbles in HepG2.2.15 cells.

[0033] 1. Culture of HepG2.2.15 liver cancer cells:

[0034] To recover the frozen cells, use DMEM medium containing 10% (v / v) fetal bovine serum, 100 U / ml penicillin and 100 U / ml streptomycin at 37°C, 5% (v / v) CO 2 Cultured in a constant temperature incubator, the medium was changed every 1 to 2 days, and routinely digested and passaged with 0.25% trypsin.

[0035] 2. Treatment of HepG2.2.15 liver cancer cells:

[0036] After the cells were well attached to the wall and the density was moderate, a combination of rapamycin 100nmol / L, Velcade 200nmol / L, and ammonium chloride 30mmol / L was added to intervene HepG2.2.15 cells for 16 hours to induce autophagosomes HBV-DRibbles.

[0037] 3. Extract HBV-DRibbles:

[0038] After the cells were treated with drugs for 16 hours, the cells were harvested, and the DRibbles in the supernatant were extracted by centrifugation. Specific steps are as follows...

Embodiment 2

[0044] Example 2: Identification of the morphology of HBV-DRibbles by transmission electron microscopy.

[0045] The extracted HBV-DRibbles were centrifuged at high speed to compress them tightly, the supernatant was discarded, the precipitate was fixed with 2.5% (v / v) glutaraldehyde, and sent to the electron microscope room for processing, and the morphology of HBV-DRibbles was observed by the microscope. Such as figure 1 Shown: Under the electron microscope, the body with membrane structure can be seen, with an average diameter of about 200-300nm (pointed by the arrow), which proves that the autophagosome of liver cancer cells is effectively recruited.

Embodiment 3

[0046] Example 3: Determination of total protein content of HBV-DRibbles (Bradford method).

[0047] 1) Completely dissolve the protein standard, take 25 μl and dilute to 100 μl with PBS;

[0048] 2) Add 0, 1, 2, 4, 8, 12, 16, and 20 μl of the standard into the 96-well plate, and add PBS to make up to 20 μl;

[0049] 3) Freeze and thaw the DRibbles to be tested repeatedly in advance, centrifuge to take the supernatant, add an appropriate volume of samples to a 96-well plate, and add PBS to make up to 20 μl;

[0050] 4) Add 200 μl of G250 staining solution to each well and let stand at room temperature for 3-5 minutes;

[0051] 5) Measure the absorbance at 595nm or other wavelengths between 560-610nm with a microplate reader;

[0052] 6) Draw a standard curve with the software ElisaCalc, and calculate the protein concentration in the sample according to the standard curve.

[0053] The protein concentration of each extraction is not exactly the same, about 1-3μg / μl.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses the application of HepG2.2.15 cell autophagy corpuscle in preparing hepatitis b virus (HBV) therapeutic vaccines. According to the application of HepG2.2.15 cell autophagy corpuscle in preparing HBV therapeutic vaccines, HBV-Dribbles which serves as a novel cross submission antigen carrier is firstly discovered, an immune mouse can generate HBV specificity cellular immune response, so that the HBV virus replication of an HBV infection mouse model is suppressed, liver cells which are infected by the HBV are effectively eliminated, and the effect is better than that of recombinant HBsAg vaccines only with a pure protective function. According to the application of HepG2.2.15 cell autophagy corpuscle in preparing HBV therapeutic vaccines, firstly the HBV-Dribbles vaccines are used for inducing the cross submission of DC cells, so that the CD8+T cellular response targeting at HBV specificity is more effectively excited, and the liver cells which are infected by the HBV virus are eliminated. The application of HepG2.2.15 cell autophagy corpuscle in preparing HBV therapeutic vaccines provides a novel idea for treating hepatitis b.

Description

technical field [0001] The invention belongs to the technical field of hepatitis B vaccine development, and in particular relates to the application of HepG2.2.15 cell autophagosomes in preparing HBV therapeutic vaccines. Background technique [0002] Hepatitis B (Hepatitis B, HB): an infectious disease caused by hepatitis B virus (Hepatitis B virus, HBV) that endangers human health. At present, there are more than 350 million chronic hepatitis B patients or carriers of HBV infection in the world, of which about 120 million are HBV carriers in my country. A considerable part will develop into liver cirrhosis or even liver cancer. At present, the drugs for the treatment of chronic hepatitis B mainly include interferon and nucleoside (acid) analogues. Due to the limitation of the target, the drug cannot effectively remove the viral cccDNA, and there will be a rebound in HBV DNA and transaminase levels after drug withdrawal; long-term drug use can cause virus mutation and dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/385A61K39/29C12N5/09A61P31/20
Inventor 王立新薛萌曹萌
Owner SOUTHEAST UNIV